Conflicts Galore: Upcoming Accelerated Approval Cancer Panel Includes Many Industry Relationships
Executive Summary
US FDA issued six conflict-of-interest waivers for the Oncologic Drugs Advisory Committee’s three-day panel to consider whether indications for three immunotherapies – Tecentriq, Keytruda and Opdivo – should be withdrawn after failed clinical outcomes studies.
You may also be interested in...
New US FDA Genetic Metabolic Adcomm Needs More Candidates
Given the enthusiasm for the new advisory committee within the rare disease community, the need for an extended deadline is somewhat surprising. FDA has not yet determined when the chair and members of the new panel will be named.
Adcomm Member Survey Shows Continued Support For Virtual Meetings After Pandemic
Despite acknowledging that fully in-person meetings overall are better, survey respondents said they still want the flexibility that virtual attendance offers.
For US FDA, Modernizing Advisory Committees Includes How Meetings Are Scheduled
Agency officials are considering developing policies for when an advisory committee meeting is appropriate, in part because of the workload associated with them. Could fewer meetings result?